Jussi Tervonen

University of Helsinki

Papers

1

Total Citations

18

H-Index

1

About

Jussi Tervonen is a leading figure in the advancement of boron neutron capture therapy (BNCT), a targeted form of radiation oncology. His key research focuses on the clinical translation of BNCT, particularly the pivotal transition from nuclear reactor-based neutron sources to next-generation proton accelerator-based systems. Tervonen’s major contribution lies in the comprehensive analysis of long-term clinical outcomes, most notably through his landmark 2022 review of 249 patients treated at Helsinki University Hospital. This work, which has garnered 18 citations, provides critical evidence on the efficacy and safety of BNCT using l-boronophenylalanine-fructose (l-BPA-F) as a boron carrier, establishing a foundational benchmark for the field. By synthesizing the Finnish experience from 1999 to 2012, Tervonen has helped shape the global roadmap for BNCT, demonstrating its potential to treat aggressive tumors with high precision. His work is essential reading for researchers and clinicians exploring non-invasive, targeted cancer therapies, marking a significant step toward making BNCT a widely accessible treatment modality.

Research Focus

Key Achievements

1
H-Index
1
Papers
18
Total Citations
18
Avg Citations/Paper
🏆 Most Cited Paper
From Nuclear Reactor-Based to Proton Accelerator-Based Therapy: The Finnish Boron Neutron Capture Therapy Experience
18 citations · 2022
📈 Most Prolific Year: 2022 (1 Papers)
🤝 Key Collaborators: 9
🏛 Institutions: University of Helsinki

Top Papers

  1. 1

Key Collaborators

Contact & Links

Available for collaboration
Content generated · 11 days ago